Identification of a distinct mutation spectrum in the SMPD1 gene of Chinese patients with acid sphingomyelinase-deficient Niemann-Pick disease

  • Huiwen Zhang1Email author,

    Affiliated with

    • Yu Wang1,

      Affiliated with

      • Zhuwen Gong1,

        Affiliated with

        • Xiaoyan Li1,

          Affiliated with

          • Wenjuan Qiu1,

            Affiliated with

            • Lianshu Han1,

              Affiliated with

              • Jun Ye1 and

                Affiliated with

                • Xuefan Gu1Email author

                  Affiliated with

                  Orphanet Journal of Rare Diseases20138:15

                  DOI: 10.1186/1750-1172-8-15

                  Received: 8 November 2012

                  Accepted: 24 January 2013

                  Published: 28 January 2013

                  Abstract

                  Background

                  Clinical observations and molecular analysis of the SMPD1 gene in Chinese patients with acid sphingomyelinase deficiency Niemann-Pick disease (NPD) are scarce.

                  Methods

                  A cohort of 27 Chinese patients diagnosed with acid sphingomyelinase deficiency, within the past five years, were collected and investigated for genotype, phenotype, and their correlations.

                  Results

                  The majority of our patients (25/27) were under 18 years of age. From the cohort group, eight (30%) fulfilled characters of type A. Four other patients experienced neurologic involvement after two years of age, these were classified as intermediate type. The remaining fifteen presented without clear neurologic involvement and were regarded as type B. One patient, from the type B group, presented with the unusual symptom of a secondary amenorrhea. Three patients, one from the type B group and two from the intermediate group, presented with pronounced proteinuria, in the late stages of the disease, indicating possible kidney involvement in NPD. Twenty-four SMPD1 gene mutations had been identified; eighteen of these are novel ones. These included four exonic small deletions/duplications (c.4delC, c.147_150del4, c.842-849dup8, c.1307-1312dup6), one termination mutation (p.Glu248X), and thirteen exonic point mutations (p.Gly336Ser, p.Trp342Cys, p.Leu382Phe, p.Pro429Leu, p.Pro430Ser, p.Trp437Arg, p.Thr451Pro, p.His461Pro, p.Ala484Val, p.Ser486Arg, p.Tyr500His, p.Pro533Leu, p.Val559Leu). Notably, eight mutations had more than one occurrence with c.4delC and p.Glu248X accounting for ~30% of all alleles. Correlation analysis of genotype and phenotype indicated eight mutations, c.842-849dup8, p.Glu248X, p.Arg230Cys, p.Trp437Arg, p.His461Pro, p.Ala484Val p.Ser486Arg, and p.Pro533Leu,to be severe mutations. Five mutations, c.4delC, p.Leu382Phe, p.Pro429Leu, p.Pro430Ser and p.Val559Leu were projected to be mild mutations. Interestingly, three intermediate individuals carried combinations of a mild mutation, c.4delC, on one allele and a severe mutation on the other allele.

                  Conclusions

                  The Chinese population may have a comparably high incidence of sphingomyelinase-deficient Niemann-Pick disease type A. This study has identified some novel genotype and phenotype correlations in this rare and devastating disorder.

                  Background

                  Acid sphingomyelinase (ASM) deficient Niemann-Pick disease (NPD) is caused by SMPD1 gene mutations and subsequent acid sphingomyelinase deficiency. It is a rare autosomal recessive disorder, usually categorized as either neuropathic type A (OMIM: 257200), non-neuropathic type B (OMIM: 607616), or clinically intermediate type [1]. Affected individuals, with the neuropathic type A, present with grossly enlarged spleens and livers, and disease onset at approximately 3 months of age. These individuals also suffer psychomotor development retardation, as evidenced by only achieving milestones of less than a 1-year developmental level, and death occurring at around three years of age. Individuals with type B usually have normal neurological development, and onset of the disease can occur from infancy to late adulthood [2]. In addition to types A and B, an intermediate form exists, this form is differentiated by presence of mental abnormality and onset at 2 to 7 years of age [3].

                  Occurrence of Niemann-Pick disease type B (NPD-B) is pan-ethnic, while the people of Ashkenazi Jewish descent have a high incidence of NPD-A. The genotype and phenotype correlation for some mutations are consistent, e.g., three common mutations, p.Arg498Leu (p.R496L), p.Leu304Pro (p.L302P), and p.Phe333SerfsX52 (990delC), account for approximately 90% of Niemann-Pick disease type A alleles in the Ashkenazi Jewish population [4]. A common NPD type B mutation, p.Arg610del (R608del), has been reported to be the predominant mutant allele (87%) in Maghreb region of North Africa [5]. A high frequency of this mutation has also been found in Spain (38%) [6], and in a report including patients from European countries, USA and Brazil (25%) [2]. In a worldwide study this mutation accounted for 12% of allelic variation [7]. In another study the p.Gln294Lys (Q292K) mutation was associated with severe and progressive neurological involvement in an intermediate type group [3]. Finally, the p.Trp32X mutation was the most frequent allele identified in an Italian NPD-B cohort study [8].

                  Currently, the mainstay treatment for Niemann-Pick disease type A/B is symptomatic. Bone marrow transplantation has been performed on a small number of NPD patients and found to be beneficial only to NPD-B individuals [9]. Enzyme replacement therapy in type B has completed phase I clinical trial. A phase II clinical trial should start in the near future. Accurate prediction of disease type from genotype would be critical for optimal treatment choices when a clinical phenotype cannot be determined based on patients’ disease presentation. Data from hundreds of North American, Western European, and Ashkenazi Jewish patients are available. Conversely, data from Chinese patients is rare [1]. In the past 5 years, 27 patients with acid sphingomyelinase deficiency were diagnosed at our center. Here we described their genotypes and compared them with each phenotype to determine any correlations. To date this is the largest mutation profile report on Chinese NPD-A/B patients.

                  Methods

                  Consent

                  This study was carried out with approval from the Institutional Review Ethics Board of Shanghai Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Informed and written consent for the collection of samples was obtained from guardians (for patients under 18 years of age) or adult patients (18 years of age and above).

                  Clinical observations

                  Clinical information involving the symptoms at onset and progression till first examination at the Endocrinology and Genetic Metabolism clinic in Xinhua Hospital was gathered from interviews with parents and from patients’ original medical charts. Special attention was paid to most the commonly occurring symptoms/conditions, such as hepatosplenomegaly, gain/loss in psychomotor developmental milestones, diarrhea, recurrent respiratory inflammation, and blood chemistry panels. Onsite physical examinations consisted of general and neurological examinations, including anthropometric parameters. Retina examinations were not conducted. Patient histories, physical examinations and follow-ups were performed by at least one of the authors.

                  Subjects

                  All subjects were from unrelated families and their parents had no consanguinity. The diagnosis of acid sphingomyelinase deficient Niemann-Pick disease in the majority cases was based on clinical presentations and a low level of ASM activity in peripheral leucocytes. One individual, case 7, was clinically diagnosed by presentation and the detection of Niemann-Pick cells in her bone marrow. The diagnosis was confirmed to be ASM deficiency post mortem; both of her parents were found to carry a “hot” mutation in the SMPD1 gene.

                  ASM activity measurement

                  Homogenates of leukocytes from patients’ peripheral blood were used to measure ASM activity as previously reported with minor modification [10]. Briefly, leukocytes, isolated from blood cell lysates, were stored at −80°C until analysis. Upon thawing samples were homogenized by sonication. Homogenates were incubated for 17 hours, at 37°C with 1.35 mM 6-hexadecanoylamino-4-methylumbelliferyl-phosphorylcholine (purchased from MOSCERDAM substrates) at pH 5.2. The reaction was stopped using 0.5 M NaHCO3, 0.5 M Na2CO3, and 0.25% Triton X-100 at pH 10.7. A 4- methylumbelliferyl standard was used. The fluorescence signals were read at the excitation wavelength 404 nm and the emission wavelength 460 nm. Protein levels were determined using the Bio-Rad BCA protein assay kit. The normal range of ASM activity is 13.7-86.1 nmol/17 h/mg protein with mean ± SD 47.2 ± 20 nmol/17 h/mg protein.

                  Sequencing of genomic DNA

                  Genomic DNA was extracted from peripheral blood using the RelaxGene blood DNA isolation kit (DNA DP319-01, Tiangen Biotech Co. Ltd., Beijing, China) according to the manufacturer’s protocol. All exons and flanking regions of the SMPD1 gene were amplified using 4 primer pairs (P1F 5′agaagggtaatcgggtgtcc3′, P1R 5′tagatgccaccctctccatc3′; P2F 5′tggaaatggaggcccaag, P2R 5′ttaggggagccaaatgaaga3′; P3F 5′actgtgagctccttgcaggt3′, P3R 5′tgctcaagggaattttcagc3′; P4F 5′ggggaggctcctcactagaa3′, P4R agctccaggaaaggagaagg3′) and sequenced bi-directionally. The obtained sequences were blasted against the SMPD1 reference gene (NM_000543) to identify mutations and/or variations. In most cases, patients’ parental DNA samples were analyzed to establish the variation origin.

                  RNA expression of SMPD1 gene

                  To study the pathogenic effects of a variation in SMPD1 intron 5, from patient number 8, IVS5+5G>C, RNA was extracted from peripheral blood stored in a PAXgene™ blood RNA tube (Qiagen) as previously reported [11]. RNA was reverse transcribed with PrimeScript RRTase (TaKaRa, Japan) and amplified with two primer pairs (P5F 5′cgtcacagcacttgtgagga3′, P5R 5′ccaggattaaggccgatgta3′; P6F 5′atcggccttaatcctggttac3′, P6R 5′ ggctttttcaccctttcctac3′) with the products sequenced bi-directionally.

                  Results

                  According to the NPD-A/B classification criteria [3], 8 individuals were assessed as type A and 4 as suffering from the intermediate form. The remaining 15 individuals, including 5 patients under 2 years of age, free of neurologic impairment, were classified as type B (Table 1). The possibility does exist that a few type B patients may devolve into the intermediate type. Type A patients accounted for 30% of the study group. In accordance with previous findings, hepatosplenomegaly was detected in all patients. Mildly elevated levels of hepatic transaminases and triglycerides, along with chronic diarrhea, were also common clinical findings. Two intermediate patients (number 9 and 10) and one type B patient (number 25) were in critical condition, presenting with a pot belly, ascites, pitting edema on lower extremities, hypoproteinemia, and proteinuria. These symptoms indicate possible kidney involvement associated with late stages of the disease.
                  Table 1

                  Clinical and molecular data of 27 Chinese patients with acid sphingomyelinase-deficient NPD

                  P

                  NPD type

                  Gender

                  Age at diagnosis

                  Age of onset

                  Phenotype and notes

                  Genotype

                  Amino acid changes

                  Intragenic position

                  ASM activity

                  1

                  A

                  male

                  1y

                  1 m

                  HP, PR, diarrhea, RG, death at 3 years 5 months

                  [c.842-849dup8] + [c.742G>T]

                  p.His284SerfsX17 / p.Glu248X

                  E2 / E2

                  0

                  2

                  A

                  female

                  2y

                  3 m

                  HP, PR, RG, PF

                  [c.842-849dup8] + [c.1451C>T]

                  p.His284SerfsX17 / p.Ala484Val

                  E2 / E5

                  0

                  3

                  A

                  female

                  11 m

                  5 m

                  HP, PG, RG, anemia, leucocytopenia, RR, died at age 1

                  [c.842-849dup8] + [c.742G>T]

                  p.His284SerfsX17 / p.Glu248X

                  E2 / E2

                  2.3

                  4

                  A

                  male

                  1y4m

                  5 m

                  HP, hypotonia,diarrhea, elevated TG, death at 20 m

                  [c.1309T>C] + [c.1598C>T; c.1621G>A]

                  p.Trp437Arg / (p.Pro533Leu; p.Ala541Thr)

                  E4 / E6

                  4.9

                  5

                  A

                  male

                  6 m

                  3 m

                  HP, hypotonia, PF

                  [c.842-849dup8] +[c.842-849dup8]

                  p.His284SerfsX17 / p.His284SerfsX17

                  E2 / E2

                  1.7

                  6

                  A

                  female

                  3 m

                  after birth

                  HP, jaundice, hypotonia,PF

                  [c.842-849dup8] + [c.742G>T; c.1445T>C]

                  p.His284SerfsX17 / (p.Glu248X; p.Phe482Ser)

                  E2 / (E2;E5)

                  0.6

                  7

                  A

                  female

                  2y

                  3 m

                  HP, hypotonia, RR, died at 1y

                  [c.842-849dup8] +[c.1458T>G]

                  p.His284SerfsX17 / p.Ser486Arg

                  E2 / E5

                  unknown

                  8

                  A

                  male

                  1y4m

                  6 m

                  diarrhea, HP, hypotonia, PR

                  [c.1382A>C] +[IVS5+5G>C]

                  p.His461Pro

                  E5

                  3.5

                  9

                  intermediate

                  male

                  7y

                  7 m

                  HP, RG, SS, MR at age 5, ascites, hypoproteinemia, died at age 9 y

                  [c.4delC] + [c.688C>T]

                  p.Arg3AlafsX76 / p.Arg230Cys

                  E1 / E2

                  3.6

                  10

                  intermediate

                  male

                  5y

                  2y

                  HP, SS, RG, anemia, leucocytopenia, ascites, hypoproteinemia,MR at age 4, died at age 6 y, PF

                  [c.4delC] + [c.742G>T]

                  p.Arg3AlafsX76 / p.Glu248X

                  E1 / E2

                  3.4

                  11

                  intermediate

                  female

                  8y

                  8y

                  HP, moderate MR

                  c.1458T>G

                  p.Ser486Arg

                  E5

                  1.2

                  12

                  intermediate

                  male

                  2y

                  6 m

                  HP, RG

                  [c.4delC] +[c.1458T>G]

                  p.Arg3AlafsX76 / p.Ser486Arg

                  E1 / E5

                  3.8

                  13

                  B

                  male

                  6y4m

                  1y

                  HP, SS, RG, anemia

                  [c.688C>T] + [c.1288C>T]

                  p.Arg230Cys / p.Pro430Ser

                  E2 / E4

                  0

                  14

                  B

                  male

                  1y10m

                  1y

                  HP, RG

                  [c.1026G>T] +[1492C>T]

                  p.Trp342Cys / p.Arg498Cys

                  E2 / E5

                  0

                  15

                  B

                  female

                  1y8m

                  after birth

                  HP, PF

                  [c.1095-1096insG] +[c.748A>C; c.1411G>A]

                  p.Phe368ValfsX22 / (p.Ser250Arg; p.Glu471Lys)

                  E3 /(E2;E5)

                  5.9

                  16

                  B

                  female

                  22y

                  22y

                  amenorrhea, pancytopenia, HP

                  [c.1144C>T] +[c.1565A>G]

                  p.Leu382Phe / p.Asn522Ser

                  E3 / E6

                  3.1

                  17

                  B

                  male

                  1y3m

                  10 m

                  HP

                  [c.4delC]+[c.4delC]

                  p.Arg3AlafsX76 /p.Arg3AlafsX76

                  E1 / E1

                  3.6

                  18

                  B

                  male

                  13y

                  2y

                  HP

                  [c.1458T>G] +[c.1675G>T]

                  p.Ser486Arg/ p.Val559Leu

                  E5 / E6

                  5.6

                  19

                  B

                  female

                  46y

                  unknown

                  HP, splenectomy at age 46 years,PF

                  [c.1565A>G] +[c.1565A>G]

                  p.Asn522Ser / p.Asn522Ser

                  E6 / E6

                  7.3

                  20

                  B

                  female

                  2y

                  1y

                  HP, RG

                  [c.759C>A] + [c. 1351 A >C]

                  p.Glu253Asp/ p.Thr451Pro

                  E2 /E5

                  2.75

                  21

                  B

                  female

                  3y

                  1y

                  HP, microproteinuria

                  undetected

                    

                  2.4

                  22

                  B

                  female

                  3y7m

                  after birth

                  diarrhea, HP, PF

                  [c.4delC]+[c.4delC]

                  p.Arg3AlafsX76 / p.Arg3AlafsX76

                  E1 / E1

                  4.8

                  23

                  B

                  female

                  1y8m

                  after birth

                  HP

                  [c.147-150del4] +[c.1144C>T]

                  p.Ser50ThrfsX26 / p.Leu382Phe

                  E1 / E3

                  2

                  24

                  B

                  male

                  7y6m

                  7y

                  HP, RG, SS

                  [c.4delC]+[c.4delC]

                  p.Arg3AlafsX76 / p.Arg3AlafsX76

                  E1 / E1

                  1.4

                  25

                  B

                  female

                  12y

                  10 m

                  HP, proteinuria, ascites, RG, splenectomy at age 9, died at age 13

                  c.1006G>A

                  p.Gly336Ser

                  E2

                  4.9

                  26

                  B

                  female

                  2y4m

                  2y

                  HP, anemia

                  [c.1286C>T] +[c.1451C>T]

                  p.Pro429Leu / p.Ala484Val

                  E4 / E5

                  3.1

                  27

                  B

                  female

                  1y

                  1y

                  HP, anemia

                  [c.1307-1312dup6] + [c.1497-1498GT>AC]

                  p.436-437dup2 / p.Tyr500His

                  E4 / E6

                  3

                  Note: HP indicated hepatosplenomegaly, PR indicated psychomotor regression, RG indicated mildly raised GPT and GST, PF indicated positive family history, RR indicated recurrent respiratory tract infection, SS indicated short stature, MR indicated mental regression. P indicated patient number, and E indicated exon. The mean ± SD of ASM activity was 47.2 ± 20 nmol/17 h/mg protein (range: 13.7 to 86.1).

                  In this study, biallelic mutations were detected in twenty-three patients and only one mutant allele could be identified in 3 patients (number 8, 11, 25) (Table 1). No mutation in the SMPD1 gene was detected in one patient (number 21), although twice assay of ASM activity from different preparation of her peripheral leucocytes had been carried out to confirm its deficiency. Several mutations, including small exon deletions (c.4delC, c.147-150del4), duplications (c.1307-1312dup6, c.842-849dup8), small insertion (c.1095_1096insG), and termination mutation (p.Glu248X), resulting in premature stop codon and rendering the enzyme noncatalytic, were considered to be pathologic. Novel and recurrent point variations, such as p.Leu382Phe, p.Ala484Val, and p.Ser486Arg were also regarded as pathologic. For those novel and private variations, their pathogenicities were assessed using PolyPhen-2 (http://​genetics.​bwh.​harvard.​edu/​pph2/​index.​shtml). Nine of them, p.Gly336Ser, p.Trp342Cys, p.Pro429Leu, p.Pro430Ser p.Trp437Arg, p.Thr451Pro, p.His461Val, p.Tyr500His, and p.Pro533Leu, were predicted to have a maximum damaging effect score and presumed to be pathological. The variation p.Val559Leu was predicted to be benign, with a score of 0.22. Considering its presence in a type B patient (number 18) with a severe mutation, p.Ser486Arg (presented below), it was regarded as a mutation with mild effect.

                  An intron variation, IVS5+5G>C, derived from a paternal allele was identified in patient number 8. To investigate its pathological influence in this patient, RNA was extracted and analyzed for SMPD1 gene expression. The result apparently showed patient 8 exclusively expressed his maternal allele carrying a p.His461Val mutation (Figure 1, Panel A), and IVS5+5G>C variation did not have any observable impact on RNA splicing (Figure 1, Panel B). In this patient, the SMPD1 gene may be paternally imprinted and the maternal allele preferentially expressed, as reported previously [12]. Our inability to detect the mutant IVS5+5G>C allele product could also be due to a premature stop codon and nonsense-mediated mRNA decay. Further functional test, such as a mini-gene system, need to be done to determine the pathogenicity of IVS5+5G>C mutation. In total, at least 24 different mutations had been found (Figure 2).
                  http://static-content.springer.com/image/art%3A10.1186%2F1750-1172-8-15/MediaObjects/13023_2012_511_Fig1_HTML.jpg
                  Figure 1

                  Failed amplification of paternal allele of the SMPD1 gene in patient number 8. The panel A showed patient 8 carried a heterozygous mutation, c.1382A>C, derived from her mother, as observed on a DNA level. However, at the RNA level the expression was in an apparently homozygous state. The panel B showed an intron variation IVS5+5G>C at the DNA level derived from this patient’s father. At the RNA level exon 5 and 6 remained unbroken, indicating lack of amplification of paternal allele.

                  http://static-content.springer.com/image/art%3A10.1186%2F1750-1172-8-15/MediaObjects/13023_2012_511_Fig2_HTML.jpg
                  Figure 2

                  Distribution of SMPD1 gene mutations from Chinese NPD-A/B patients. A total of 24 different mutations had been identified in this Chinese patient cohort. The eight recurrent mutations are in red, and the presumed severe mutations are marked by blue pentagram.

                  Three patients (number 15, 6, and 4) carried two sequence variations on a single SMPD1allele. In patient 15, both p.Ser250Arg and p.Glu471Lys mutations were of maternal inheritance. Previously, the p.Ser250Arg mutation has been reported in combination with a premature stop codon, in a Dutch patient with a mild form of type A NPD [10]. In this study, we were unable to determine the pathogenicity of p.Glu471Leu. Similarly, in patient 6, a termination, p.Glu248X, and an exon point mutation, p.Phe482Ser, were identified on the same allele. Another variation at the same codon, p.Phe482Leu, had been documented in a type B patient [7]. The nature of p.Phe482Ser was unclear here. Another variation, p.Ala541Thr, was identified on the same allele as p.Pro533Leu, in patient 4. To fully understand the complete effects of these three variations, expression studies need to be conducted as previously reported [10].

                  It is very interesting that with the exception of five exon point mutations, c.688C>T (p.Arg230Cys) [7], c.748A>T(p.Ser250Arg) [13], c.759C>A (p.Asp253Glu) [14], c.1565A>G (p.Asn522Ser) [10], c.1492C>T (p.Arg498Cys) [15], and a small insertion, c.1095_1096insG [7], the majority of mutations, including c.4delC, c.147_150del4, c.1307-1312dup6, c.842-849dup8, p.Glu248X, p.Gly336Ser, p.Trp342Cys, p.Leu382Phe, p.Pro429Leu, p.Pro430Ser, p.Trp437Arg, p.Thr451Pro, p.His461Pro, p.Ala484Val, p.Ser486Arg, p.Pro533Leu, p.Val559Leu and p.Tyr500His, were novel according the SMPD1 gene mutation database (http://​www.​hgmd.​cf.​ac.​uk). These newly detected mutations have been deposited in the public databases dbSNP, with the batch accession number 1057561.

                  Among all mutations, 8 of them, c.4delC, c.842-849dup8, p.Glu248X, p.Ser486Arg, p.Asn522Ser, p.Leu382Phe, p.Arg230Cys, and p.Ala484Val, occurred more than once and accounted for 61.1% of all disease alleles (Table 2). The two most frequent mutations were c.4delC and c.842-849dup8 and consisted of 29.6% of the total alleles.
                  Table 2

                  Genotype/phenotype correlation for 8 recurring mutation in Chinese patients

                  Mutation

                  Exon

                  Number of Alleles

                  Phenotype

                  c.4delC

                  1

                  9

                  3 type B patients in homozygosity; 3 intermediate patients in heterozygosity

                  c.842-849dup8

                  2

                  7

                  1 type A patient in homozygosity; 5 type A patients in heterozygosity

                  c.742G>T (p.Glu248X)

                  2

                  4

                  3 type A patients in heterozygosity; 1 intermediate patient in heterozygosity

                  c.1458T>G (p.Ser486Arg)

                  5

                  4

                  2 type A patients in heterozygosity;1 intermediate patient in heterozygosity; 1 type B patient in heterozygosity

                  c.1565A>G (p.Asn522Ser)

                  6

                  3

                  1 type B patient in homozygosity;1 type B patitent in heterozygosity

                  c.1144C>T (p.Leu382Phe)

                  3

                  2

                  2 type B patients in heterozygosity

                  c.688T>C (p.Arg230Cys)

                  2

                  2

                  1 type B patients in heterozygosity, 1 intermediate patient

                  c.1451C>T (p.Ala484Val)

                  5

                  2

                  1 type A patient in heterozygosity; 1 type B patient in heterozygosity

                  Two recurrent mutations, c.842-849dup8 and p.Glu248X, are presumed to cause premature stop codon and are considered severe mutations. In accordance with a severe genotype, 3 individuals (number 1, 3, and 6) carrying a combination of mutations with c.842-849dup8 on one allele and p.Glu248X on the other, had typical type A presentation. Since both severe alleles are required to result in NPD-A and at least one severe allele is required to intermediate type NPD, p.Trp437Arg (in number 4), p.Ala484Val (in number 2), p.Arg230Cys (in number 9), p.His461Pro (in number 8), p.Ser486Arg (in patient 7 and 12), and p.Pro533Leu (in number 4) were estimated to be severe mutations. In consideration that at least one mild mutation is necessary to result in NPD-B, p.Pro430Ser (in number 13), p.Val559Leu (in number 18), p.Leu382Phe (in number 23), p.Pro429Leu (in number 26) were estimated to be mild mutations.

                  Discussion

                  In the largest NPD database, at Mount Sinai School of Medicine, ~20% presented with type A, of these 66% were Ashkenazi Jewish [1]. Although NPD-A has a lower incidence in Chinese NPD patients than in Ashkenazi Jewish, it is still of notable occurrence. In this study, there were only two patients (number 16 and 19) of adult age, the rest ranged in age from 3 months to 12 years, with a mean age of 5.6 years. Therefore, these finding could be biased with respect to patients’ age.

                  Beside the classical presentation discussed earlier [2, 16], growth restriction has been described in patients with NPD-B [17]. In our observations, growth restrictions were more apparent in patients 5 years of age and above. For example, patient 9, 10, 13 and 24 had Z scores for height lower than −2, meeting the criteria of short stature. Conversely, two adult patients (patient 16 and 19), with the p.Asn522Ser mutation, had normal height. Patient 16, an adult, sought medical treatment for secondary amenorrhea initially and was, only then, diagnosed with NPD-B. Amenorrhea is rarely described comorbidity with NPD-B [2]. From this data, we propose the menstrual cycles of adult female NPD patients should be observed.

                  Although NPD-B is a multi-system disease, kidney involvement is rarely described. Imaging studies found that the kidneys were enlarged by Niemann-Pick cells infiltration [18]. In the end stages of an intermediate NPD patient, kidney biopsies found foamy podocytes, vacuolated tubular epithelial cells, and accumulation of foam cells in the interstitium [19]. In this study, B ultrasonography identified abnormal signals in bilateral adrenal pelvis and bilateral large kidney size in one patient (number 13). Three other patients (number 9, 10, and 25), in the late stages of the disease, presented with proteinuria, hypoproteinemia, and ascites. In addition, patient 21 had microproteinuria. All these observations substantiate kidney involvement in NPD.

                  In this study we found Chinese patients to be free of “hot” mutations identified in other ethnicities, such as p.Arg498Leu [20], p.Leu304Pro [21], p.Phe333SerfsX52 [22], p.Arg610del [23], p.Trp393Gly [24], and p.Q294K [14]. Here, the recurrent mutations were novel, e.g. c.4delC, c.842-849dup8, p.Glu248X, p.Leu382Phe, p.Ser486Arg, p.Ala484Val. As a group, these mutations accounted for 51.9% of all alleles.

                  With regard to phenotype/genotype correlations, c.842-849dup8 was homozygous in one NPD-A patient (number 5), heterozygous in five other NPD-A patients (number 1, 2, 3, 6, and 7), and not present in any NPD-B patients, thus c.842-849dup8 is considered a severe mutation. Another mutation, c.4delC, was found to be homozygous in 3 type B patients (17, 22, and 24) and heterozygous in 3 intermediate patients (9, 10, and 12). The oldest homozygous c.4delC patient was 7 years of age and without neurologic involvement (patient 24), which indicated c.4delC is a non-neurotoxic mutation resulting in comparatively low severity of NPD. Interestingly, when considering the position of this mutation, c.4delC was expected to produce a complete enzyme deficiency. However, we observed it was associated with a mild form of the disease. It has been previously reported that a second methionine (Met33) can rescue mutations involving the traditional start methionine [8], this may be occurring in the c.4delC mutation as well.

                  The c.1565A>G (p.Asn522Ser) mutation resulted in ~10% of wild type activity and has been described previously in a NPD-B patient [10]. Both patients with homoallelic (number 19) or heterallelic (number 16) p.Asn522Ser were free of neurologic involvement. Additionally, the disease onset occurred in their adulthood and the patients had normal statures, supporting the presumed mild nature of the mutation.

                  Previous finding indicate that patients with the intermediate phenotype carried at least one severe mutation [8]. Here, three intermediate patients (number 10, 11, 12) had one severe mutation, p.Glu248X and p.Ser486Arg (twice occurring) respectively. Besides, three of four intermediate patients had the common c.4delC (number 9, 10, 12), which was assumed to be a mild mutation. On this basis, p.Arg230Cys was presumed to be a severe mutation considering its presence with c.4delC in patient 9. The combination of a severe mutation on one allele and a mild mutation on the other allele indicates their intermediate status both in clinical phenotype and genotype.

                  In conclusion, a high portion of Chinese NPD patients have been diagnosed with type A. The SMPD1 gene mutation profiles in Chinese patients are markedly different from reported data of other ethnic groups. Two novel mutations, c.4delC and c.842-849dup8 had significantly high incidences in this cohort of patients. Our data provides novel genotype and phenotype correlation of ASM deficiency and has important implications in genetic counseling and in decisions regarding therapy for care givers. In the future it may aid in large scale carrier screening. One of the shortcomings of this study is that all data comes from one hospital. For this rare disease, data accumulated from multiple centers of China would strengthen these observations.

                  Declarations

                  Acknowledgement

                  Zhang H was supported by National Natural Science Foundation of China (81071121, 30801257), Shanghai Rising-Star Program (12QH1401800), and Shanghai Municipal Health Bureau (2012112). Gu X was supported by by the Major Program of Shanghai Committee of Science and Technology (11dz195030) and The National Key Technology R&D Program (2012BAI09B04).

                  Authors’ Affiliations

                  (1)
                  Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine

                  References

                  1. Schuchman EH: The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis 2007, 30:654–663.PubMedView Article
                  2. McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E, Brodie SE, Mendelson D, Skloot G, Desnick RJ, et al.: A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics 2008, 122:e341-e349.PubMedView Article
                  3. Wasserstein MP, Aron A, Brodie SE, Simonaro C, Desnick RJ, McGovern MM: Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediatr 2006, 149:554–559.PubMedView Article
                  4. Schuchman EH, Miranda SR: Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. Genet Test 1997, 1:13–19.PubMed
                  5. Vanier MT, Ferlinz K, Rousson R, Duthel S, Louisot P, Sandhoff K, Suzuki K: Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa. Hum Genet 1993, 92:325–330.PubMedView Article
                  6. Rodriguez-Pascau L, Gort L, Schuchman EH, Vilageliu L, Grinberg D, Chabas A: Identification and characterization of SMPD1 mutations causing Niemann-Pick types A and B in Spanish patients. Hum Mutat 2009, 30:1117–1122.PubMedView Article
                  7. Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH: The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet 2002, 71:1413–1419.PubMedView Article
                  8. Pittis MG, Ricci V, Guerci VI, Marcais C, Ciana G, Dardis A, Gerin F, Stroppiano M, Vanier MT, Filocamo M, Bembi B: Acid sphingomyelinase: identification of nine novel mutations among Italian Niemann Pick type B patients and characterization of in vivo functional in-frame start codon. Hum Mutat 2004, 24:186–187.PubMedView Article
                  9. Schneiderman J, Thormann K, Charrow J, Kletzel M: Correction of enzyme levels with allogeneic hematopoeitic progenitor cell transplantation in Niemann-Pick type B. Pediatr Blood Cancer 2007, 49:987–989.PubMedView Article
                  10. Desnick JP, Kim J, He X, Wasserstein MP, Simonaro CM, Schuchman EH: Identification and characterization of eight novel SMPD1 mutations causing types A and B Niemann-Pick disease. Mol Med 2010, 16:316–321.PubMedView Article
                  11. Zhang H, Li J, Zhang X, Wang Y, Qiu W, Ye J, Han L, Gao X, Gu X: Analysis of the IDS gene in 38 patients with Hunter syndrome: the c.879G>A (p.Gln293Gln) synonymous variation in a female create exonic splicing. PLoS One 2011, 6:e22951.PubMedView Article
                  12. Simonaro CM, Park JH, Eliyahu E, Shtraizent N, McGovern MM, Schuchman EH: Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease. Am J Hum Genet 2006, 78:865–870.PubMedView Article
                  13. Sikora J, Pavlu-Pereira H, Elleder M, Roelofs H, Wevers RA: Seven novel acid sphingomyelinase gene mutations in Niemann-Pick type A and B patients. Ann Hum Genet 2003, 67:63–70.PubMedView Article
                  14. Pavlu-Pereira H, Asfaw B, Poupctova H, Ledvinova J, Sikora J, Vanier MT, Sandhoff K, Zeman J, Novotna Z, Chudoba D, Elleder M: Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study. J Inherit Metab Dis 2005, 28:203–227.PubMedView Article
                  15. Ricci V, Stroppiano M, Corsolini F, Di Rocco M, Parenti G, Regis S, Grossi S, Biancheri R, Mazzotti R, Filocamo M: Screening of 25 Italian patients with Niemann-Pick A reveals fourteen new mutations, one common and thirteen private, in SMPD1. Hum Mutat 2004, 24:105.PubMedView Article
                  16. McGovern MM, Pohl-Worgall T, Deckelbaum RJ, Simpson W, Mendelson D, Desnick RJ, Schuchman EH, Wasserstein MP: Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr 2004, 145:77–81.PubMedView Article
                  17. Wasserstein MP, Larkin AE, Glass RB, Schuchman EH, Desnick RJ, McGovern MM: Growth restriction in children with type B Niemann-Pick disease. J Pediatr 2003, 142:424–428.PubMedView Article
                  18. Simpson WL Jr, Mendelson D, Wasserstein MP, McGovern MM: Imaging manifestations of Niemann-Pick disease type B. AJR Am J Roentgenol 2010, 194:W12-W19.PubMedView Article
                  19. Grafft AC, Fervenza CF, Semret HM, Orloff S, Sethi S: Renal involvement in Neimann-Pick Disease. Clinical Kidney Journal 2009, 2:448–451.
                  20. Levran O, Desnick RJ, Schuchman EH: Niemann-Pick disease: a frequent missense mutation in the acid sphingomyelinase gene of Ashkenazi Jewish type A and B patients. Proc Natl Acad Sci USA 1991, 88:3748–3752.PubMedView Article
                  21. Levran O, Desnick RJ, Schuchman EH: Identification and expression of a common missense mutation (L302P) in the acid sphingomyelinase gene of Ashkenazi Jewish type A Niemann-Pick disease patients. Blood 1992, 80:2081–2087.PubMed
                  22. Levran O, Desnick RJ, Schuchman EH: Type A Niemann-Pick disease: a frameshift mutation in the acid sphingomyelinase gene (fsP330) occurs in Ashkenazi Jewish patients. Hum Mutat 1993, 2:317–319.PubMedView Article
                  23. Levran O, Desnick RJ, Schuchman EH: Niemann-Pick type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients. J Clin Invest 1991, 88:806–810.PubMedView Article
                  24. Mihaylova V, Hantke J, Sinigerska I, Cherninkova S, Raicheva M, Bouwer S, Tincheva R, Khuyomdziev D, Bertranpetit J, Chandler D, et al.: Highly variable neural involvement in sphingomyelinase-deficient Niemann-Pick disease caused by an ancestral Gypsy mutation. Brain 2007, 130:1050–1061.PubMedView Article

                  Copyright

                  © Zhang et al.; licensee BioMed Central Ltd. 2013

                  This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                  Advertisement